Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  Asaleo Care Limited    AHY   AU000000AHY8

ASALEO CARE LIMITED

(AHY)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/20
1.05 AUD   +2.44%
09/17ASALEO CARE : Appointment of Chief Financial Officer
PU
08/24ASALEO CARE : Change of Director's Interest Notice
PU
08/17ASALEO CARE : First Half Financial Results Media Release
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Asaleo Care : First Half 20 Results Presentation

share with twitter share with LinkedIn share with facebook
08/17/2020 | 06:43pm EDT

2020 Half Year Results

Sid Takla

CEO & Managing Director

Campbell Richards

Chief Financial Officer

18 August 2020

Important Notice and Disclaimer

This presentation has been prepared by Asaleo Care Limited ACN 154 461 300 (Company). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activities current as at 18 August 2020 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. It has been prepared by the Company with due care but no representation or warranty, express or implied, is provided in relation to the accuracy, reliability, fairness or completeness of the information, opinions or conclusions in this presentation.

Not an offer or financial product advice: The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly, in any member of the Group or any other financial products (Securities). This presentation is for information purposes only.

Financial data: All dollar values are in Australian dollars ($ or A$). Any financial data in this presentation is unaudited.

Effect of rounding: A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

Underlying financial information: As a result of non-recurring income and expenditure in 1H20 and 1H19, underlying financial information is included in this presentation. A reconciliation between the Underlying financial information and Asaleo Care Group's statutory financial information is included within the Interim Financial Report. The statutory results in this Report are based on the Interim Final Financial Report reviewed by PwC.

Past performance: The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

Future performance: This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "could", "would", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this presentation include statements regarding the Company's future financial performance, growth options, strategies and new products . Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements, including projections, guidance on future operations, earnings and estimates (if any), are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No representation is given that the assumptions upon which forward looking statements may be based are reasonable. This presentation contains statements that are subject to risk factors associated with the Group's industry. These forward-looking statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to earnings, capital expenditure, cash flow and capital structure risks and general business risks. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward-looking statements in this presentation speak only as of the date of this presentation. Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.

Non-IFRSterms: This presentation contains certain financial data that has not been prepared in accordance with a definition prescribed by Australian Accounting Standards or International Financial Reporting Standards, including the following measures: EBITDA, EBITDA margin, EBIT, maintenance capital expenditure and growth capital expenditure or performance improvement capital expenditure. Because these measures lack a prescribed definition, they may not be comparable to similarly titled measures presented by other companies, and nor should they be considered as an alternative to financial measures calculated in accordance with Australian Accounting Standards and International Financial Reporting Standards. Although the Company believes that these non-IFRS terms provide useful information to recipients in measuring the financial performance and the condition of the business, recipients are cautioned not to place undue reliance on such measures.

No liability: The Company has prepared this presentation based on information available to it at the time of preparation, from sources believed to be reliable and subject to the qualifications in this document. To the maximum extent permitted by law, the Company and its affiliates, related bodies corporate (as that term is defined in the Corporations Act), shareholders, directors, employees, officers, representatives, agents, partners, consultants and advisers accept no responsibility or liability for the contents of this presentation and make no recommendations or warranties. No representation or warranty, express or implied, is made as to the fairness, accuracy, adequacy, validity, correctness or completeness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, the Group does not accept any responsibility or liability including, without limitation, any liability arising from fault or negligence on the part of any person, for any loss whatever arising from the use of the information in this presentation or its

contents or otherwise arising in connection with it.

2

Key Highlights

Focus on customer, delivering profitable market share growth

  • Revenue growth of 10%
    • Continued investment in our brands delivering market share growth
    • COVID-19panic buying boosted sales in March/April, eased back in May/June
    • Successful NPD ranging & activation
  • EBITDA growth of 24%
    • Incremental margin from sales growth
    • Pulp price benefits, partly offset by unfavourable FX and significant insurance cost increases
  • Proactive portfolio management - decision made to exit loss-making Baby Diaper business in NZ
  • Strong cashflow - debt reduced a further 14% this half (55% reduction in the last 18 months)

Financial Performance

Capital Efficiency

*

*

*

On track to deliver full year Underlying EBITDA guidance at upper end of $84-$87m range

3

* Continuing operations excludes the Baby division

Asaleo Care Business by Segment

B2B

Retail

Australia & New Zealand

Australia & New Zealand

New Zealand

Pacific Islands

Professional

Incontinence

Feminine

Incontinence

Consumer Tissue

Tissue and

Hygiene

Healthcare

Hygiene

Retail

Personal Care

Revenue*

EBITDA*

52%

48%

49%

51%

B2B

RETAIL

* Continuing operations: excludes the Baby division

4

Business to Business (B2B) Segment Performance

Strong growth in Incontinence Healthcare, resilience in Professional Hygiene

  • Professional Hygiene revenue up 2.5%:
    • COVID-19panic buying in March/April across all categories. Heightened hygiene awareness driving increased demand on soaps, sanitisers, hand towel and wiping products
    • Lockdown measures have heavily impacted sales into HORECA, Office Cleaning & Education sectors partly offset by strong performance in Healthcare and Food-processing sectors due to increased hygiene requirements
  • Incontinence Healthcare revenue up 11%:
    • Increased focus on quality of patient care driving strong TENA sales
    • Share growth supported by our ability to supply incremental COVID driven demand
    • Some customers holding extra inventory to assure supply of an essential product during COVID-19, we anticipate this will correct in H2
  • B2B margin favourable 2.4pp - favourable pulp prices plus cost savings delivered from our new manufacturing investment in NZ last year, partly offset with unfavourable FX and insurance cost increases

B2B

Continuing

Continuing

%

$M

1H20

1H19

Revenue

111.3

106.4

4.6%

EBITDA

24.4

20.8

17.3%

EBITDA %

21.9%

19.5%

2.4pp

B2B NSV History ($M)

Hero Systems - % of Professional Hygiene sales

34%

36%

37%

115.2

32%

108.4

111.5

112.0

29%

30%

102.8

105.8

27%

93.4

96.0

97.4

104.0

106.2

106.4

111.3

2014

2015

2016

2017

2018

2019

2020

2014

2015

2016

2017

2018

2019

1H20

H1

H2

5

COVID-19 Implications on the B2B segment

Resilience in B2B earnings driven by industry sector and regional diversification

Lower away-from-home activity has impacted

sales in the HORECA, Education & Office cleaning

sectors. This has partly been offset by increased

hygiene requirements in Healthcare, Food

Processing and general Facility Cleaning Services

Second COVID-19 wave in Victoria temporarily

Professional Hygiene Sales by Region*

NT

Professional Hygiene Sales by Industry sector*

ManufacturingGovernment/

dampening away-from-home activity, further

impacting Professional Hygiene performance in

that state. Victoria represents less than 20% of

total Professional Hygiene sales

Sales activity in other Australian states has

improved post the first COVID wave but overall

away-from-home activity is expected to remain

down on last year

Removal of COVID-19 domestic lockdown

restrictions in New Zealand has seen a strong

WA

SA

NZ

QLD

TAS

VICNSW

Food Service

Facility

Cleaning

Services

Healthcare

Education

Other

bounce back in June/July sales.

COVID-19 is not a direct driver of an increase in

consumption in Incontinence Healthcare, but it

has heightened focus on "quality of care"

ACT

Food

Processing HORECA

underpinning strong growth for TENA

*2019 full year data for Professional Hygiene

6

COVID-19 Implications on the B2B division

The increased focus on hygiene bodes well for Asaleo Care growth

Opportunities

  • Change in personal and workplace hygiene habits and requirements leading to increased usage of sanitisers, soap, hand towel and wiping products
  • Increased awareness of effectiveness of drying hands driving shift from air dryers to paper towels
  • Greater acceptance of single use disposable products that are more hygienic
  • Increase in requests for no-touch sensor dispensers
  • Strong customer and consumer sentiment towards locally manufactured product providing a competitive advantage for Asaleo Care

Challenges

  • Away-From-Homeactivity impacted heavily in certain industry sectors. Ongoing lockdown measures will continue to impact Professional Hygiene sales
  • Victorian Government Schools initiative to provide free feminine care products - revenue from replenishment service impacted by school lockdowns

Accelerated New Product Development

Emphasising our expertise in hygiene

New sanitisers + mounting

solutions

Portable wiping caddies

Disinfecting wipers

7

Retail Segment Performance

Profitable market share growth achieved in all key categories

  • Both Australian and New Zealand businesses were favourably impacted in 1H20 by unprecedented demand in March and April from COVID-19 panic buying
  • Market share growth achieved in all key categories driven by:
    • Continued investment in the Brands
    • Local manufacturing capabilities provided ability to respond quickly to COVID-19 demand spikes
    • Extended range and distribution
    • NPD including new Libra packaging, Tena Men and Tena Discreet
  • Consumer Tissue New Zealand Revenue up 12.4%
  • Feminine Care Revenue up 24.4%
  • Incontinence Care Revenue up 18.7%
  • Margin improvement of 2.9pp driven by retailer cancellation of promotional activities during COVID panic-buying, favourable pulp costs, slightly offset with unfavourable foreign exchange and insurance cost increases. Some A&P spend was deferred to 2H20 to reduce pressure on supply network

Retail

Continuing

Continuing

%

$M

1H20

1H19

Revenue

103.6

89.6

15.6%

EBITDA

25.0

19.0

31.6%

EBITDA %

24.1%

21.2%

2.9pp

Continuing Retail NSV History ($M)

3 year 1H CAGR of 7%

105.9

98.1

99.3

98.4

88.0

91.6

100.7

101.6

91.7

90.1

84.7

89.6

103.7

2014

2015

2016

2017

2018

2019

2020

H1

H2

8

COVID-19 Implications on the Retail division

Our focus remains on underlying share growth activity

Opportunities

  • Customer & Consumer support of locally produced products has increased markedly as a result of COVID-19. Communications to emphasise
    that Asaleo Care is the only local manufacturer of Feminine and Incontinence Care products
  • More in-home activity will drive higher

consumption of consumer tissue products in NZ

Extra Wide & Long

Night Pants

Black Pants

  • Focus will remain on activity to drive share growth including extension of ranging and distribution of NPD e.g. Libra Extra Wide & Long, Libra Night pants, TENA Discreet black pants

Challenges

  • Some range reviews postponed due to COVID-19, delaying further opportunities of ranging of NPD
  • Victorian Government Schools initiative to provide free feminine care products - consumption impacted by school lockdowns

9

COVID-19 Impact on Company Operations

Keeping our team safe & ensuring supply of our essential products

  • Our priority has been to ensure all our staff remain safe and healthy - No employees or contractors have contracted COVID
  • Measures have been put in place to ensure all manufacturing operations and distribution centres remain in operation - no closures or down-time experienced
    • Management have conducted business continuity planning exercises centered around potential COVID-19 scenarios - contingency plans have been put in place as a result
    • Rigorous cleaning regimens implemented in all work-places
  • All office-based staff in Australia have been and still are remote-working since early March (note, NZ office staff returned to work upon removal of lockdown measures)
  • Although additional costs incurred to maintain social distancing and lift hygiene requirements, these have been offset by savings in travel costs
  • Asaleo Care has not claimed any Government assistance either in Australia or New Zealand (e.g. Job Keeper)

10

Safety - always a key priority

  • Sale and closure of higher-risk manufacturing sites coupled with continued investment in state-of-the-art converting assets built to higher safety standards is creating a safer working environment for our people
  • Ongoing investment in our OH&S management systems and a focus on building a culture of individual accountability have been key pillars in the improvement of our safety metrics
  • During the period, we successfully set up two new Distribution Centers in Queensland and Victoria with no major incidents
  • Our Pacific Islands facility has recently achieved 6 years of no lost time injuries

Key Safety Metrics

16.6

13.6

11.4

11.9

11.6

10.7

11.1

8.6

8.0

6.2

6.5

5.9

4.9

5.3

3.0

2016

2017

2018

2019

1H20

LTIFR

TIFR

Severity Rate

LTIFR: Lost Time Injury Frequency Rate (no. of lost time injuries per million hours worked)

TIFR: Lost Time and Medical Treatment injuries per million hours worked

Severity Rate: Days lost per lost time injury (Includes employees and contractors)

11

Environment, Sustainability and Governance

Key initiatives underpinning our focus on social responsibility

  • We launched our first Reconciliation Action Plan to support the national reconciliation movement in Australia for Aboriginal and Torres Strait Islander peoples, communities and organisations
  • We advanced our commitment to addressing risks associated with Modern Slavery by conducting independent ethical audits across the supply chain of our key sites
  • We strengthened our partnership with Ronald McDonald House Charities for supply of toilet rolls, hand towel and dispensers to Chapter Houses across Australia
  • Libra partnered with Share the Dignity to support supply of feminine hygiene products to women and girls in difficult socio- economic circumstances

As a member of Sedex (Supplier Ethical Data Exchange), successfully completed three independent SMETA ethical audits at our manufacturing sites to ensure responsible business practices across Sedex's four pillars of Labour, Health& Safety and Environment & Business Ethics.

12

Half 1 Summary

Earnings Resilience

  • Financial performance during the half was strong despite challenging operating conditions resulting from COVID-19
  • Investment in the brands delivered profitable market share growth
  • No interim dividend as we focus on debt reduction and a strong Balance Sheet
  • Proactive portfolio management improving focus and diverting investment to higher margin, higher growth categories

Financials

Half Year Results 2020

Campbell Richards

Chief Financial Officer

18 August 2020

(completion end of Q1

Asaleo Care Financial Performance

Year on year revenue growth across both Retail

(+15.6%) and B2B (+4.6%) through

unprecedented demand driven by COVID-19

panic buying and richer mix of product being

sold

Improved Gross Margins through lower pulp

Asaleo Care

1H20

1H19

%

$M

Revenue from continuing operations

215.0

196.1

9.6%

Cost of sales

(116.5)

(112.4)

3.6%

Gross profit

98.5

83.7

17.7%

costs, benefits from new converting machine

installed in 2H19, partly offset with higher

insurance costs and unfavourable FX

SM&A costs higher due to full year impact of

investment last year in sales resources to drive

topline growth and increased advertising and

promotion investment. Also includes a quarter

of a year of stranded costs post divestment of

Consumer Tissue Australia

2019)

  • A portion of the A&P spend has been deferred to the second half due to the COVID-19 situation

Distribution expenses

(20.8)

(18.3)

Sales, Marketing & Admin

(28.4)

(25.6)

Other income

0.1

0.0

EBITDA

49.4

39.8

Depreciation and amortisation

(12.8)

(11.5)

EBIT

36.6

28.3

Net finance costs

(4.1)

(7.3)

NPBT

32.5

20.9

Income tax expense

(9.8)

(5.8)

NPAT from continuing operations

22.8

15.2

Non-recurring expenses

(0.1)

(2.6)

Discontinued operations

(3.9)

(5.2)

Statutory NPAT

18.8

7.3

13.7%

10.9%

24.1%

11.3%

29.3%

-43.8%

55.5%

69.0%

50.0%

-96.2%

-25.0%

157.5% 15

Underlying to Continuing Operations Reconciliation

Exit of NZ Baby Diaper Business

  • Announced withdrawal from the NZ Baby Diaper category on 25th June 2020, including closure of the Te Rapa manufacturing facility
  • Decision is consistent with the company's focus on exiting businesses that generate poor returns
  • Closure expected to complete during 2H20 i.e. sell remaining inventory and manufacturing assets
  • Baby Division is now disclosed as a
    "Discontinued Operation" for both the current year and prior year
  • The Baby division generated an EBITDA loss YTD FY20 of $3.2m and $0.4m in the prior corresponding period

Half 1 2020

Half 1 2019

Underlying

Underlying

Baby Disc

A$m

inc Baby

Baby Disc Ops

Continuing

inc Baby

Ops

Continuing

Revenue

219.6

4.6

215.0

202.0

5.9

196.1

EBITDA

46.2

(3.2)

49.4

39.4

(0.4)

39.8

Variance A$m

Variance %

Underlying

Underlying

Baby Disc

inc Baby

Baby Disc Ops

Continuing

inc Baby

Ops

Continuing

Revenue

17.6

(1.3)

18.9

9%

-22%

10%

EBITDA

6.8

(2.8)

9.6

17%

700%

24%

16

Reconciliation of Continuing to Statutory NPAT

Baby Diaper Trading Loss

  • YTD Baby Diaper division loss reclassified to Discontinued Operations which includes additional trade spend to sell through excess inventory

Baby Diaper Closure Costs

  • Costs associated with redundancies, property make good, onerous lease and fixed asset write- off at the Te Rapa manufacturing facility
  • Asset sales to be undertaken in H2

Australian Consumer Tissue Business

  • Costs relating to the transition to new distribution facilities post sale of the Australian Consumer Tissue business
  • Redundancy costs related to right-sizing the organization post sale of Consumer Tissue Australia

A$m

1H20

NPAT from continuing operations

22.8

Non-recurring expenses

(0.1)

Baby loss before tax 1H20

(3.6)

Baby closure costs

(6.0)

Australian Consumer Tissue Business

(2.2)

Tax

7.9

Statutory NPAT

18.8

17

Pulp - Global supply and demand dynamics keep prices low, depreciation in local currencies partly offsetting cost benefit

Market

Pulp prices at low point in cycle driven by over

Hardwood - RISI China Delivered Price

capacity and falling demand

Prices have stabilized at this lower level

2015

2016

2017

2018

2019

2020

Hardwood prices have been impacted by a

global oversupply which has been further

850

elevated due to postponement of paper mill

800

maintenance programs

Tonne

Softwood prices have been stagnant with lower

750

demand being slightly offset with lower

Per

Price

700

capacity due to supply constraints

Pulp

Depreciation of local currencies partly

650

offsetting benefit of lower pulp prices

USD

600

Asaleo Care

Continue to source and use high quality FSC

550

certified pulp in all paper products

500

manufactured

6-month lag of pulp pricing into COGS still

450

2015

2015

2015

2016

2016

2016

2017

2017

2017

2018

2018

2018

2019

2019

2019

2020

2020

2020

2015

2015

2015

2016

2016

2016

2017

2017

2017

2018

2018

2018

2019

2019

2019

2020

2020

2020

applies

Jan

Mar

May

Jul

Sep

Nov

Jan

Mar

May

Jul

Sep

Nov

Jan

Mar

May

Jul

Sep

Nov

Jan

Mar

May

Jul

Sep

Nov

Jan

Mar

May

Jul

Sep

Nov

Jan

Mar

May

Jul

Sep

Nov

Indicative impact of US$ pulp price changes - a ~6 month lag from pulp purchase price

being set to pricing reflected in Cost of Sales has been taken into consideration

* Source: Risi,Inc. The price Asaleo Care pays is subject to commercial arrangements

18

that impact price. Asaleo Care primarily sources Softwood from Canada and New

Zealand and Hardwood from South America.

Strong free cash flow generation

Free Cash Flow (FCF)

  • FCF of $34.1m
  • Strong EBITDA (continuing operations) growth delivered by both Retail and B2B
  • Favourable Working Capital movement due to timing of sales and customer payments. Increased inventory offset with increased payables

Cash Flow Applied to Capital Allocation:

  • Two cent unfranked FY19 final dividend paid in April
  • Strategic capital investment includes progress payments for NZ converting asset and cost of dispensers for Victorian Government schools feminine care program

Free Cash Flow (FCF) ($m)

FCF Applied to Capital

Allocation ($m)

19

Net Debt

Continued focus on debt reduction driving a strong Balance Sheet

Leverage Ratio

  • Leverage ratio at 30 June 2020 is 1.4x, down from 1.95x at 31 December 2019
  • Reduced internal leverage ratio target from a range of 1.5x - 2.5x EBITDA to 1.0x - 2.0x EBITDA to ensure a strong balance sheet and improve credit metrics

Net Debt Movement

  • Decrease of $20.4m to $118.9m at 30 June 2020 (Dec-19: $139.3m)

Debt Facilities

  • Negotiations currently underway to extend tenor of Facility A

Debt maturity Profile ($m)

$70.0

$65.0

$27.5

$40.0

$22.5

$25.0

Facility A

Facility B

Facility C

Series A

Series B

31 July 21

31 July 23

31 July 22

Guaranteed

Guaranteed

Series Notes

Series Notes

26 June 25

26 June 28

Drawn

Available

Total Facilities

$250m

Undrawn Debt

$67.5m

Drawn Debt

$182.5m

Cash and Cash Equivalents

$63.6m

Net Debt

$118.9m

20

Capital Expenditure

Growth Capital Expenditure

  • Progress payments for the new converting equipment in NZ Tissue plant. Final payment of $1.6m to be paid in H2
  • Investment in dispensers for the Victorian Government Schools feminine care program

Maintenance CAPEX to remain in-line with historical average

Depreciation:

  • Depreciation for continuing operations will be higher than prior years, due to commencing depreciation of the investment made in the new B2B Tissue converting asset in NZ
  • AASB 16: Lease amortisation is included in overall depreciation since 2019

Continuing Capital Expenditure ($m)

Depreciation ($m)

$8.5

$21.8

$10.0

$3.7

$4.7

$4.2

$4.8

$15.0

$2.9

$15.3

$14.9

$15.4

$15.7

$15.5

$11.3

$13.0

$10.9

$11.0

$8.0

$6.4

2015

2016

2017

2018

2019

1H20

2015

2016

2017

2018

2019

1H20

Maintenance

Growth

Depreciation

Lease Amortisation

21

Outlook

Full-Year Profit guidance remains unchanged

Sales Revenue

Brand investment will continue to drive underlying sales growth

Continued lockdown measures in H2 will negatively impact Professional

Hygiene sales, although partly offset by increased demand in hygiene-critical

sectors (i.e. healthcare, food processing)

Expect panic buying from March and April to continue to unwind in the second

half of the year

EBITDA

Full year Underlying EBITDA guidance expected to be at the upper end of the

$84m to $87m range.

H2 impacted by:

- unwind of H1 panic buying in H2

- less favourable foreign exchange levels in hedged positions

- deferral of H1 planned brand investment to H2

Capital Management

No interim dividend declared - conservative cash management in these

uncertain times

Strong H2 cashflow will be applied to reduce debt and further strengthen the

balance sheet

No major Growth Capex activity planned for H2

Disclaimer

Asaleo Care Limited published this content on 18 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 August 2020 22:42:06 UTC


share with twitter share with LinkedIn share with facebook
All news about ASALEO CARE LIMITED
09/17ASALEO CARE : Appointment of Chief Financial Officer
PU
08/24ASALEO CARE : Change of Director's Interest Notice
PU
08/17ASALEO CARE : First Half Financial Results Media Release
PU
08/17ASALEO CARE : First Half 20 Results Presentation
PU
08/17ASALEO CARE : Appendix 4D for the half year ended 30 June 2020
PU
08/11ASALEO CARE : issues voluntary recall of Sorbent facial tissue product in New Ze..
PU
08/10ASALEO CARE : Webcast of 2020 Half Year Results
PU
07/20ASALEO CARE : launches inaugural Reconciliation Action Plan
PU
04/21ASALEO CARE : Results of 2020 AGM - 21 April 2020
PU
03/19ASALEO CARE : Notice of Annual General Meeting/Proxy Form
PU
More news
Financials
Sales 2020 429 M 303 M 303 M
Net income 2020 34,0 M 24,0 M 24,0 M
Net Debt 2020 102 M 71,6 M 71,6 M
P/E ratio 2020 16,2x
Yield 2020 2,19%
Capitalization 570 M 402 M 402 M
EV / Sales 2020 1,56x
EV / Sales 2021 1,50x
Nbr of Employees -
Free-Float 62,9%
Chart ASALEO CARE LIMITED
Duration : Period :
Asaleo Care Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASALEO CARE LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 1,16 AUD
Last Close Price 1,05 AUD
Spread / Highest target 23,8%
Spread / Average Target 10,9%
Spread / Lowest Target -10,5%
EPS Revisions
Managers
NameTitle
Sid Takla Chief Executive Officer, MD & Director
Harry Boon Independent Non-Executive Chairman
Campbell R. Richards Chief Financial Officer
Mats Berencreutz Non-Executive Director
Sue M. Morphet Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASALEO CARE LIMITED-0.94%394
KIMBERLY-CLARK CORPORATION11.47%51 433
UNICHARM CORPORATION37.27%28 488
ESSITY AB-0.80%23 893
HENGAN INTERNATIONAL GROUP COMPANY LIMITED-0.45%8 435
VINDA INTERNATIONAL HOLDINGS LIMITED93.23%4 131